DOTA-ECL1i

고객리뷰

Based on 1 Customer Validation

DOTA-ECL1i is a conjugate of the CCR2 inhibitor ECL1i (HY-P11553) and DOTA. When radiolabeled with 68Ga, DOTA-ECL1i serves as a PET tracer that targets CCR2 expression. DOTA-ECL1i can be used in research related to pulmonary fibrosis, cardiac injury, abdominal aortic aneurysm inflammation, atherosclerosis, head and neck cancer, and pancreatic cancer.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

  • Purity: 98.06%
  • CAS No.: 2850189-48-7
  • 화학식: C58H94N14O18S
  • 분자량:1307.51
  • 보관:

    Sealed storage, away from moisture.

    Powder   -80°C, 2 years , -20°C, 1 year

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

  • Biological Activity
  • Chemical Information
  • 용액&용해도
  • 순도&문서
  • References
  • Help & FAQs

All Radionuclide-Drug Conjugates (RDCs) Isoforms

More
MOQ
Minimum order quantity
100 mg

견적 받기 해외재고보유

Other size
견적 받기
Please select quantity
Amount: USD 0.00